The quest for the optimal biomarker: is extending the spectrum of targeted
PIK3CA
mutations in breast cancer carcinoma worthwhile?
Ann Transl Med
.
2023 Oct 25;11(11):393.
doi: 10.21037/atm-23-1608.
Epub 2023 Aug 29.
Authors
Stanislas Quesada
1
,
William Jacot
1
Affiliation
1
Institut régional du Cancer de Montpellier (ICM), INSERM U1194, Montpellier University, Montpellier, France.
PMID:
37970606
PMCID:
PMC10632578
DOI:
10.21037/atm-23-1608
No abstract available
Keywords:
Breast cancer; PIK3CA; alpelisib; next-generation sequencing (NGS).
Publication types
Editorial
Comment